Cognizant extends partnership with biopharma firm Gilead, estimated deal size at $800 million

economictimes.indiatimes.com:

biopharmaceutical company Gilead Sciences for an additional five years, including renewal and expansion of Cognizant's services, for a total expected value of $800 million. Under the agreement, the NASDAQ-listed IT firm will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives to accelerate its digital transformation.

This collaboration will streamline various parts of Gilead's business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer, according to its exchange filing. Gilead has partnered with Cognizant for more than three years now to adopt technologies designed to run business operations, new product launches and improving IT processes for research, manufacturing, and commercialisation of its products, the release said.

Cognizant plans to use Generative Artificial Intelligence (GenAI) and AI automation to improve Gilead’s customer service experience and assist it in driving greater manufacturing efficiencies. «The GenAI advances should enable Gilead to provide greater visibility and transparency about the company’s treatments to patients and internal employees globally.

Gilead will leverage Cognizant’s Neuro IT service for AI automation innovation, which should help Gilead to bring products to market more efficiently,» the release added. «Working together our teams will be leveraging the latest technologies from automation to cloud computing, and Generative AI to help Gilead bring its products to market faster, more efficiently, and with higher customer satisfaction,» said said Surya Gummadi, executive vice president and president of Cognizant Americas.